Although currently available targeted therapies, such as gefitinib and alfa, are targeted specifically for the epidermal growth factor receptor (EGFR) pathway in NSCLC, drug resistance is inevitable (Wei et al., 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.